Multidrug-Resistant Bacteria in Immunocompromised Patients

Author:

Duhaniuc Alexandru12ORCID,Păduraru Diana3,Nastase Eduard-Vasile45ORCID,Trofin Felicia1ORCID,Iancu Luminița-Smaranda12ORCID,Sima Cristina-Mihaela15,Dorneanu Olivia-Simona15ORCID

Affiliation:

1. Department of Preventive Medicine and Interdisciplinarity—Microbiology, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania

2. National Institute of Public Health—Regional Center of Public Health, 700465 Iasi, Romania

3. “Dr. C.I. Parhon” Clinical Hospital, 700503 Iasi, Romania

4. Department of Internal Medicine II—Infectious Diseases, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania

5. Clinical Hospital of Infectious Diseases “Sf. Parascheva”, 700116 Iasi, Romania

Abstract

The increasing incidence of antibiotic resistance in bacteria is a major problem in terms of therapeutic options, especially in immunocompromised patients, such as patients from intensive care units (ICUs), HIV-positive patients, patients with malignancies or transplant patients. Commensal bacteria, especially anaerobes, serve to maintain microbial stability by preventing overpopulation with pathogenic bacteria. In immunocompromised patients, microbiota imbalance caused by antibiotic therapy and decreased host immunity favors intestinal overpopulation with pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infections. Infections with multidrug-resistant (MDR) bacteria pose major challenges to the establishment of appropriate treatment and lead to increased mortality. Asymptomatic colonization with MDR bacteria usually precedes infection and tends to persist for long periods of time, and in immunocompromised patients, colonization with MDR bacteria is a risk factor for systemic infections. This review aims to assess the relation between colonization and infection with MDR bacteria in immunocompromised patients such as ICU patients, HIV-positive patients and cancer patients and to identify the prevalence and patterns of MDR bacterial colonization and infection in this category of patients.

Funder

University of Medicine and Pharmacy “Grigore T. Popa”

Publisher

MDPI AG

Reference85 articles.

1. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis;Tacconelli;Lancet Infect. Dis.,2018

2. World Health Organization (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization.

3. European Centre for Disease Prevention and Control (2022). Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2020, ECDC.

4. European Centre for Disease Prevention and Control (2022). Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2021, ECDC.

5. European Centre for Disease Prevention and Control (2023). Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2022, ECDC.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3